Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 15/06/18 at 09:45am

Another busy in week in pharma has seen a number of companies release promising data on their drugs, Roche's study highlighting the benefit of Ocrevus to MS patients. While in other news, J&J is looking to rid itself of excess weight and Mylan get hit by an FDA sucker punch.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Danger of Sanofi’s dengue vaccine confirmed in new study

A study that thoroughly analyses the impact of Sanofi’s dengue vaccine has confirmed what was feared – children without prior exposure to dengue had an increased risk of hospitalisation and the development of severe dengue.

9. EU gives nod to expanded label for AZ’s Tagrisso

AstraZeneca scored another success with Tagrisso in Europe, by receiving an expanded marketing authorisation for Tagrisso in the first-line setting for patients with locally-advanced or metastatic non-small cell lung cancer, with activating epidermal growth factor receptor mutations.

8. Vaccination rates in parts of US fall to dangerous levels

The anti-vaxxer movement is the scourge of meticulously researched science and yet, in certain states in the US, it seems to be gaining ground.

7. Takeda shareholders try to buck Shire deal

A small group of Takeda shareholders have started making a lot of noise over its $62 billion deal for Shire, and they’re not happy with the decision.

6. AbbVie/Roche gain FDA approval for blockbuster treatment

AbbVie and Roche chalked up a major success, after the FDA gave its approval for Venclexta, in combination with rituximab, for the treatment of patients with chronic lymphocytic leukaemia.

5. J&J continues to shed assets, with $2.1bn diabetes unit sale

Just last week, Johnson & Johnson announced that it had received an offer from Fortive for its medical sterilisation unit, potentially bringing in $2.8 billion. It then revealed that it has accepted a $2.1 billion offer for LifeScan from Platinum Equity.

4. Brexit negotiations: Is the public’s health a priority?

The Brexit decision has created a huge amount of question marks for many industries and each is vying with each other for the ear of the UK Government. This feature states the case that, for the public’s health, the healthcare and life science industries should be at the front of the queue.

3. FDA knocks back Mylan's Advair generic for second time

The FDA rejected Mylan’s generic version of GlaxoSmithKline’s Advair for the second time following its knockback last year, citing “minor deficiencies” in its efficacy as reason for the decision.

2. Roche's Ocrevus extends time-to-wheelchair by 7 years in progressive MS patients

Roche lifted the curtain on more promising data at Phase 3 for its humanised anti-CD20 monoclonal antibody Ocrevus (ocrelizumab), showing that the therapy could provide a range of “meaningful disability benefits” to multiple sclerosis patients.

1. Celgene showcases strong Otezla data in psoriatic arthritis

Celgene revealed positive new data for its phosphodiesterase 4 inhibitor Otezla in the treatment of active psoriatic arthritis in patients whose disease has progressed despite the use of prior conventional disease-modifying anti-rheumatic drugs and/or biologics.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches